This segment focuses on the research, development, and commercialization of small molecule drugs targeting viral infections. Enanta's R&D activities include drug discovery, preclinical studies, and clinical trials across various phases. The company utilizes its robust, chemistry-driven approach and drug discovery capabilities to develop innovative therapies. This segment addresses significant unmet medical needs in areas such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and hepatitis B virus (HBV). The company's collaboration with AbbVie for HCV treatments, including paritaprevir and glecaprevir, demonstrates its market positioning and competitive advantage. Future opportunities include expanding the pipeline with novel antiviral agents and advancing clinical programs. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials to demonstrate safety and efficacy. Partnerships with companies like AbbVie and Shionogi & Co., Ltd. are crucial for commercialization and market access.

This segment is dedicated to developing small molecule drugs for the treatment of liver diseases, with a primary focus on chronic hepatitis C virus (HCV). Enanta's research and development efforts include identifying and developing NS3 and NS3/4A protease inhibitor compounds. The company leverages its expertise in medicinal chemistry and drug development to create effective therapies. This segment addresses the significant global burden of liver diseases, aiming to improve patient outcomes and reduce the need for liver transplants. The collaboration with AbbVie, which resulted in the commercialization of HCV treatments, highlights the segment's market positioning and success. Future opportunities include expanding the portfolio to address other liver diseases and exploring novel therapeutic approaches. Regulatory and clinical aspects involve obtaining regulatory approvals and conducting clinical trials to demonstrate the safety and efficacy of the developed drugs. Partnerships with pharmaceutical companies are essential for commercialization and market access.